Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Monoclonal antibodies represent an exciting class of therapeutics against respiratory viral
infections. Notwithstanding their specificity and affinity, the conventional parenteral …

1. BACKGROUND A cluster of pneumonia cases was reported by the Wuhan Municipal
Health Commission, China, Hubei Province, resulting in the identification of a novel …

Convalescent plasma has been extensively tested during the COVID-19 pandemic as a
transfusion product. Similarly, monoclonal antibodies have been largely administered either …

An HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-
CoV-2 (nasal antibody spray or NAS) was developed to strengthen COVID-19 management …

Neutralising monoclonal antibody (mAb) is an important weapon in our arsenal for
combating respiratory viral infections. However, the effectiveness of neutralising mAb has …

The ability to deploy decentralized laboratories with autonomous and reliable disease
diagnosis holds the potential to deliver accessible healthcare services for public safety …

BACKGROUND As Omicron is prompted to replicate in the upper airway, neutralizing
antibodies (NAbs) delivered through inhalation might inhibit early-stage infection in the …

Abstract Coronavirus Disease 2019 (COVID-19) pandemic is severely impacting the world,
and tremendous efforts have been made to deal with it. Despite many advances in vaccines …

Previously, we identified an antibody combination A8G6 that showed promising efficacy in
COVID-19 animal models and favorable safety profile in preclinical models as well as in a …